Puma Biotechnology Reports Q1 2026 Earnings Results
Puma Biotechnology, Inc. (PBYI) held its earnings conference call on May 7, 2026, to discuss financial results for the first quarter of 2026. The company reported an earnings per share (EPS) of -$0.04, which beat analyst estimates by $0.09. Total revenue for the quarter reached $44.80 million, representing a 2.61% year-over-year decline but exceeding expectations by $2.80 million. Key company participants included CEO Alan Auerbach, CFO Maximo F. Nougues, and senior executives from marketing and sales divisions. The call featured a presentation by management followed by a Q&A session with analysts, including Salvatore Caruso from TD Cowen. Mariann Ohanesian, Senior Director of Investor Relations, opened the call by highlighting the availability of the detailed news release, presentation slides, and webcast archive on the company's investor website. The discussion included standard forward-looking statement disclaimers regarding future expectations and risks. This event provides investors and stakeholders with critical insights into Puma Biotechnology's recent financial performance, operational updates, and strategic outlook for the remainder of 2026, reflecting the company's current market position in the biotechnology sector.
Wire timeline
Puma Biotechnology Reports Q1 2026 Earnings Results
Puma Biotechnology, Inc. (PBYI) held its earnings conference call on May 7, 2026, to discuss financial results for the first quarter of 2026. The company reported an earnings per share (EPS) of -$0.04, which beat analyst estimates by $0.09. Total revenue for the quarter reached $44.80 million, representing a 2.61% year-over-year decline but exceeding expectations by $2.80 million. Key company participants included CEO Alan Auerbach, CFO Maximo F. Nougues, and senior executives from marketing and sales divisions. The call featured a presentation by management followed by a Q&A session with analysts, including Salvatore Caruso from TD Cowen. Mariann Ohanesian, Senior Director of Investor Relations, opened the call by highlighting the availability of the detailed news release, presentation slides, and webcast archive on the company's investor website. The discussion included standard forward-looking statement disclaimers regarding future expectations and risks. This event provides investors and stakeholders with critical insights into Puma Biotechnology's recent financial performance, operational updates, and strategic outlook for the remainder of 2026, reflecting the company's current market position in the biotechnology sector.
All Articles on Seeking Alpha